Evidence map›Paper›PMID 32509099›Full record

ArticleInternational journal of clinical and experimental pathology2020

Overexpressed gene signature of EPH receptor A/B family in cancer patients-comprehensive analyses from the public high-throughput database.

Nam Nhut Phan, Shirui Liu, Chih-Yang Wang, Hui-Ping Hsu, Ming-Derg Lai, Chung-Yen Li, Chien-Fu Chen, Chung-Chieh Chiao, Meng-Chi Yen, Zhengda Sun and 1 more

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Nam Nhut PhanNTT Institute of Hi-Technology, Nguyen Tat Thanh University Ho Chi Minh City 700000, Vietnam.
Shirui LiuDepartment of Mechanical Engineering, School of Engineering, San Francisco State University San Francisco, CA 94143, USA.
Chih-Yang WangDepartment of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University Tainan 11031, Taiwan.
Hui-Ping HsuDepartment of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan 704, Taiwan.
Ming-Derg LaiDepartment of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University Tainan 11031, Taiwan.
Chung-Yen LiDepartment of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University Tainan 11031, Taiwan.
Chien-Fu ChenSchool of Chinese Medicine for Post-Baccalaureate, I-Shou University Kaohsiung 84001, Taiwan.
Chung-Chieh ChiaoSchool of Chinese Medicine for Post-Baccalaureate, I-Shou University Kaohsiung 84001, Taiwan.
Meng-Chi YenDepartment of Emergency Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung 80708, Taiwan.
Zhengda SunDepartment of Radiology, University of California San Francisco, San Francisco, CA 94143, USA.
Jia-Zhen JiangEmergency Department, Huashan Hospital North, Fudan University Shanghai 201508, People's Republic of China.
Fudan University · CNKaohsiung Medical University · TWNational Cheng Kung University Hospital · TWSan Francisco State University · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although a previous study suggested that erythropoietin-producing hepatoma (EPH) receptors play important roles in tumor progression and the overexpression of EPHs in cancer patients is related to poor prognoses, high-throughput gene expression profiling of EPH family members in different types and subtypes of cancers has so far not been conducted. We herein carried out a series of bioinformatic analyses on expressive profiles of every EPH member across 21 different types of clinical cancers versus matched normal tissues gathered from the Oncomine platform. We validated these results by protein expression study of all EPHs family members by The Human Protein Atlas repository. Our results uncovered the overexpression of most EPH subunits in numerous cancer types, especially the dramatic overexpression of six EPHs members, namely EPHA1, EPHA2, EPHA3, EPHA4 and EPHB1, EPHB2, EPHB3, EPHB4 in bladder, colorectal, esophageal, gastric, and prostate cancers. Furthermore, EPHB2 was specifically highly expressed in cervical cancer, EPHA3 in liver cancer, and EPHB1 in uterine cancer. Collectively, expressive profiles of these EPHs were confirmed and correlated with different cancer subtypes as potential biomarkers. This study provides useful information for further studies on cancer development and clinical treatments.

Indexed as

bioinformaticsephrinserythropoietin-producing hepatocellular type-A (EPHA) receptorerythropoietin-producing hepatocellular type-B (EPHB) receptorErythropoietin-producing hepatoma (EPH) receptorsmedical oncology

Identifiers

PMID32509099
PMCPMC7270671
OpenAlexW3033897119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.